Open label, Phase I study to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics, and biomarker status of BAY 73-4506 in patients with advanced malignancies
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2015
At a glance
- Drugs Regorafenib (Primary)
- Indications Liver cancer; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- Sponsors Bayer
- 07 Jun 2017 Biomarkers information updated
- 20 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Sep 2013 Planned end date changed from 1 Aug 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.